Proactive Investors - Run By Investors For Investors

Anavex to advance Alzheimer’s drug with larger Phase 2/3 trial

It comes as the US FDA provided Anavex with guidance on its proposed strategy for the drug candidate.
Anavex to advance Alzheimer’s drug with larger Phase 2/3 trial
Anavex believes its approach will be more efficient

Anavex Life Sciences (NASDAQ:AVXL, OTCMKTS:AVXL) has told investors it will advance regulatory filings for the development of its Alzheimer’s drug.

It comes as the US Foods and Drugs Administration (FDA) provided the company with guidance on its proposed strategy for the drug candidate.

The company said it will advance a larger and more innovative Phase 2/3 trial for the drug, ANAVEX 2-73.

Christopher Missling, Anavex chief executive, said: “By implementing a different, innovative trial design for ANAVEX 2-73 in Alzheimer’s treatment, it is believed that this is more efficient than a conventional Phase 2 study since it is designed to reduce the risk of a Phase 3 trial failure, as well as receiving the best quality information we can about ANAVEX 2-73.”

Missling highlights that the prior Phase 2a trial used Adaptive Design and Population Pharmacokinetics/Pharmacodynamics (PK/PD) modelling, which he says was a “major strength” which benefits the drugs development for Alzheimer’s disease as well as other central nervous system (CNS) diseases.

The proposed Phase 2/3 trial will be double-blinded, randomized and placebo-controlled.

In pre-market trading the Nasdaq quoted shares were up 87 cents, about 27%, changing hands at US$4.11. It comes after a sharp drop in the price, down to a US$3.24 close, on Tuesday.

View full AVXL profile View Profile

Anavex Life Sciences Timeline

Related Articles

April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
May 20 2019
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use